Printer Friendly

ELAN STARTS HUMAN CLINICAL TRIALS OF ADVANCED TRANSDERMAL SYSTEM TO REPLACE INJECTABLE DRUGS

 ELAN STARTS HUMAN CLINICAL TRIALS OF ADVANCED
 TRANSDERMAL SYSTEM TO REPLACE INJECTABLE DRUGS
 ATHLONE, Ireland, April 15 /PRNewswire/ -- Elan Corporation, plc (AMEX: ELN) said its patented Panoderm system has entered human clinical evaluation for transdermal delivery of three classes of drugs now administered only by injection.
 The novel wristwatch-size device, which smoothly nudges drugs through the skin over 24-hours with the assist of low-levels of electrical current, is designed to achieve more consistent blood levels of therapeutic compounds, decrease drug use and lower drug-related health care costs.
 "We hope the days of the needle are numbered in the administration of many life-saving drugs which can't be taken orally and won't pass through the skin with a passive patch system," says Donald E. Panoz, Elan's chairman and chief executive officer. "Panoderm avoids the peak and valley blood levels of drug inherent with injectables, assuring a more prolonged therapeutic benefit."
 Panoz said Panoderm's success will help reduce nursing costs, especially when physicians order frequent intra-day dosing of injectables. "A single Panoderm cartridge will provide the desired therapeutic coverage for a full 24-hours or longer in most cases," he added.
 Expanded Trials For IV System
 The company also said it recently expanded clinicals of its patented Panoject system, a wearable IV device initially planned for hospital administration of powerful painkilling opiates such as morphine and other analgesics. Elan previously said it plans to file a 510k device approval for this product with the U.S. FDA by year-end.
 "These developments reflect tremendous progress at Drug Research Corporation (DRC) which was funded by a rights offering in November 1990," said Panoz.
 Panoderm and Panoject have basically identical microelectronic systems to control the amount of drug entering the blood stream. Both also employ disposable drug-containing cartridges. Panoderm delivers drugs transdermally, while Panoject administers them intravenously via standard catheters.
 In concurrent clinicals, Elan is testing delivery of anticogulants, several peptide-based drugs and a range of antiemetics for prevention of nausea and vomiting, two prevalent side effects of many chemotherapy agents. Panoject is additionally being tested with a wide range of analgesics.
 Both systems consists of two basic components -- a reusable watch- size device housing the microelectronic controls, and a disposable cartridge containing the drug, which snaps into the back of the device.
 Each drug cartridge carries encoded instructions to program the system to automatically deliver the proper dosage over pre-set times without any patient involvement. With Panoject, bolus injections are possible by pushing an override button on the face of the device.
 The Panoderm system, based on the principles of iontophoresis, electrically charges skin tissue with positive and negative ions which draw drug from the cartridge and into the blood stream.
 The Panoject system employs an electrolytic pump with no moving parts. Its operation is infinitely controllable, it can be switched on and off at will and infuse drugs at any rate specified.
 Elan is a leader in the specialized health care field of advanced reformulation and drug delivery, concentrating on improved drug absorption and utilization. It operates research and manufacturing facilities in Athlone, Ireland, Gainesville, Ga., Enschede, Netherlands, Manila, Philippines, Brea, Calif., and Cambridge, Mass.
 -0- 4/15/92
 /CONTACT: Brian Crotty of Elan Corporation, 800-252-3526, or Thomas Redington of Redington Inc., 203-222-7399 or 212-926-1733, for Elan Corporation/
 (ELN) CO: Elan Corporation, plc ST: IN: MTC SU:


PS-LR -- NY007 -- 8515 04/15/92 09:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 15, 1992
Words:561
Previous Article:STANLEY NET SALES AND EARNINGS UP 11 PERCENT; EPS UNCHANGED
Next Article:INTER-REGIONAL FINANCIAL GROUP REPORTS BEST QUARTER IN COMPANY'S HISTORY; NET EARNINGS UP 106 PERCENT ON 50 PERCENT NET REVENUE GAIN


Related Articles
/FIRST ADD -- NY081 -- ELAN'S NICOTINE PATCH APPROVED BY FDA/
COURT RULES IN FAVOR OF CYGNUS MOTION FOR SUMMARY JUDGMENT; DISMISSES IMPORTANT PARTS OF PATENT INFRINGEMENT SUIT
CYGNUS: LEADING RUSSIAN SCIENTISTS JOIN CYGNUS ELECTROPORATION TEAM
ELAN ANNOUNCES COMMENCEMENT OF HUMAN CLINICAL TRIALS OF A POTENTIALLY NON-TOXIC CANCER TREATMENT
CYGNUS REACHES SETTLEMENT WITH ELAN OVER NICOTINE PATCH SUIT
USE OF ELAN'S PATCH DOUBLES QUIT RATE AT ONE YEAR
Elan Issues a Further Report on Development Pipeline.
Cognetix Forms Collaboration With Elan to Develop Drug for Acute Pain Management.
Emisphere Technologies and Elan Agree to New Terms for Note Repayment.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters